Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|October 2, 2013
- Pharmaceutical Technology-10-02-2013
- Volume 37
- Issue 10
LCMS-8050 Mass Spectrometer Increases Quality Analysis
LCMS-8050 Mass Spectrometer Increases Quality Analysis
The LCMS-8050 triple quadrupole mass spectrometer can perform both positive and negative ion analysis in a single run for faster throughput. The LCMS-8050 achieves high sensitivity through a patented ion optics system, a designed heated ESI probe, and UFsweeper III Collision Cell. The LCMS-8050 offers multiple reaction monitoring (MRM) speeds of 555 ch/sec and maintains spectrum quality, sensitivity, and accuracy at scan speeds up to 30,000 μ/sec. The Synchronized Survey Scan function allows users to obtain MRM data while simultaneously performing qualitative MS/MS scans. The LCMS-8050 provides 5-millisecond polarity switching and maintains ion intensity during polarity switching at high speeds. The ion source features a cable-free, tubeless housing when switching from ESI to APCI or dual-ionization mode.
Articles in this issue
almost 13 years ago
Q&A with Amie Gehris, Dow Water and Process Solutionsalmost 13 years ago
Unraveling the Mystery of Ireland's Pharm-Attractionsalmost 13 years ago
Report from: Middle East and North Africaalmost 13 years ago
Maintaining and Verifying the Cold Chainalmost 13 years ago
Ensuring Compliance with Drug Accountability Requirementsalmost 13 years ago
The Expense of Vision in Outsourcingalmost 13 years ago
Tracking Quality in Drug Manufacturingalmost 13 years ago
USP Seeks Input on Standards for Plastic Packaging Systemsalmost 13 years ago
RheocalcT Software Tests Parameters and Data CollectionRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.